You are currently browsing the archives for April 2018.
Displaying 43 - 43 of 43 entries.

Barr Pharmaceuticals confirms patent problem of Focalin XR Barr Pharmaceuticals.

Barr Pharmaceuticals confirms patent problem of Focalin XR Barr Pharmaceuticals, Inc. Offers verified that its subsidiary, Barr Laboratories, Inc., provides initiated a problem of the patents shown for Focalin XR extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is produced for the U.S. For Novartis Pharmaceuticals Company by Elan Holdings Inc. Barr filed its Abbreviated New Medication Application including a paragraph IV qualification for a generic Focalin XR item with the U.S. Food & Medication Administration in June 2007, and received notification of the application’s acceptance for submitting in October 2007.